Pharmion Corporation (Nasdaq: PHRM) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Thalidomide Pharmion® for the treatment of untreated multiple myeloma in the European Union.
Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow.
Thalomid® (thalidomide) was approved May 2006 by the USFDA in combination with dexamethasone for the treatment of newly diagnosed multiple myeloma.
In Australia, New Zealand, Turkey, Israel, South Korea and Thailand, Thalidomide Pharmion is approved for the treatment of multiple myeloma after the failure of standard therapies.
Find more details from the press release.
Comment Preview